Opinions Split On Newly Approved Myeloma Therapies At ASH
This article was originally published in Scrip
Doctors debated which new therapies they would prefer to use for the treatment of multiple myeloma and when they thought emerging treatments should become an option for their patients, during the first day of the Annual Meeting for the American Society of Hematology (ASH).
You may also be interested in...
Darzalex made a splash with impressive Phase III data in relapsed multiple myeloma at the EHA and ASCO meetings, but a range of other drugs are on the way, including a next-generation CD38 inhibitor from Sanofi, checkpoint inhibitors and Roche's BCL-2 Venclexta.
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.